Top Markets
#1 DeFiChain DeFiChain +2,516.54%
#2 Akedo Akedo +207.46%
#3 ONFA ONFA +54.25%
#4 Metaplex Metaplex +23.40%
#5 Osaka Protocol Osaka Protocol +21.54%
#6 Wrapped Krown Wrapped Krown +20.00%
#7 Talus Network Talus Network +19.98%
#8 DODO DODO +17.78%
#9 Black Phoenix Black Phoenix +15.09%
#10 Magma Finance Magma Finance +14.74%
Coin of the day
DeFiChain DeFiChain
Paramètres
Langue
FRANçAIS
Devise
USD
Thème
Valbiotis SA Valbiotis SA

Valbiotis SA

ALVAL
Classement en actions #16315
Valbiotis SA engages in the research and development of health nutrition... Valbiotis SA engages in the research and development of health nutrition products to prevent and combat metabolic and cardiovascular diseases. The company develops TOTUM-63 that is in Phase II/III clinical trials for the treatment of type 2 diabetes; TOTUM-070, which is in Phase II clinical trials to treat hypercholesterolemia; and TOTUM-854 that is in Phase II/III clinical trials for arterial hypertension. It also develops TOTUM-448 for the treatment of patient with non-alcoholic fatty liver disease. It has a strategic partnership with Nestlé Health Science. Valbiotis SA was incorporated in 2014 and is headquartered in Périgny, France.
Prix de l'action
$0.94180721
Capitalisation boursière
$22.26M
Changement (1 jour)
0.38%
Changement (1 an)
-14.35%
Pays
FR
Échange Valbiotis SA (ALVAL)

Catégorie

Healthcare
Ratio P/S pour Valbiotis SA (ALVAL)
Ratio P/S au July 2026 TTM : 20.66
Selon les derniers rapports financiers et le cours de l'action de Valbiotis SA, le ratio cours/ventes actuel (TTM) est 20.66. À la fin de 2023, le ratio P/S était de 13.17.
Historique du ratio P/S pour Valbiotis SA de 2015 à 2026
Ratio P/S à la fin de chaque année
Année Ratio P/S Changez
2026 (TTM) 20.66 -84.94%
2024 137.18 942.04%
2023 13.17 -71.62%
2022 46.39 -77.96%
2021 210.51 1,341.15%
2020 14.61 -87.37%
2019 115.65 -24.97%
2018 154.14 -97.25%
2017 5.61K 10,113.84%
2016 54.92 355.39%
2015 12.06 0.00%
Ratio P/S pour des entreprises similaires ou concurrentes
Entreprise Ratio P/S Différence de Ratio P/S Pays
Novo Nordisk A/S Novo Nordisk A/S
Novo Nordisk A/S
NVO.US
4.33 -79.03%
DK
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
9.86 -52.26%
US
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
REGN.US
4.53 -78.07%
US
UCB SA UCB SA
UCB SA
UCB.BR
5.72 -72.33%
BE
Argenx SE Argenx SE
Argenx SE
ARGX.US
16.03 -22.43%
NL